Lixte Biotechnology Holdings Inc (LIXT) - Total Liabilities
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXT) has total liabilities worth $521.42K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Lixte Biotechnology Holdings Inc (LIXT) cash conversion ratio to assess how effectively this company generates cash.
Lixte Biotechnology Holdings Inc - Total Liabilities Trend (2005–2024)
This chart illustrates how Lixte Biotechnology Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Check LIXT cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Lixte Biotechnology Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Lixte Biotechnology Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
White Horse Bhd
KLSE:5009
|
Malaysia | RM121.98 Million |
|
Hotel Royal Chihpen
TWO:5704
|
Taiwan | NT$129.10 Million |
|
Cue Biopharma
NASDAQ:CUE
|
USA | $18.40 Million |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
USA | $4.26 Million |
|
KPS Consortium Bhd
KLSE:9121
|
Malaysia | RM180.13 Million |
|
Tulikivi Oyj A
HE:TULAV
|
Finland | €19.10 Million |
|
InfoBank Corporation
KQ:039290
|
Korea | ₩28.87 Billion |
|
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
|
USA | $86.35 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Lixte Biotechnology Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lixte Biotechnology Holdings Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lixte Biotechnology Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lixte Biotechnology Holdings Inc (2005–2024)
The table below shows the annual total liabilities of Lixte Biotechnology Holdings Inc from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $318.28K | +1.41% |
| 2023-12-31 | $313.86K | -20.50% |
| 2022-12-31 | $394.79K | +30.32% |
| 2021-12-31 | $302.93K | +39.90% |
| 2020-12-31 | $216.52K | -8.98% |
| 2019-12-31 | $237.90K | +12.79% |
| 2018-12-31 | $210.91K | -43.46% |
| 2017-12-31 | $373.02K | +70.60% |
| 2016-12-31 | $218.65K | -23.45% |
| 2015-12-31 | $285.64K | +4.46% |
| 2014-12-31 | $273.44K | -15.02% |
| 2013-12-31 | $321.77K | +23.21% |
| 2012-12-31 | $261.15K | -25.54% |
| 2011-12-31 | $350.75K | +79.81% |
| 2010-12-31 | $195.06K | -35.04% |
| 2009-12-31 | $300.26K | -19.97% |
| 2008-12-31 | $375.20K | +48.78% |
| 2007-12-31 | $252.18K | +102.55% |
| 2006-12-31 | $124.50K | +896.02% |
| 2005-12-31 | $12.50K | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more